• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Diabetes . Clinical Characteristics and Outcomes of COVID-19 in Patients with Type 2 Diabetes in Turkey: A Nationwide Study (TurCoviDia)

tetano

Editor, Senior Moderator
J Diabetes


. 2021 Mar 2.
doi: 10.1111/1753-0407.13171. Online ahead of print.
Clinical Characteristics and Outcomes of COVID-19 in Patients with Type 2 Diabetes in Turkey: A Nationwide Study (TurCoviDia)


Alper Sonmez[SUP] 1 [/SUP], Ibrahim Demirci[SUP] 2 [/SUP], Cem Haymana[SUP] 2 [/SUP], Ilker Tasci[SUP] 3 [/SUP], Selcuk Dagdelen[SUP] 4 [/SUP], Serpil Salman[SUP] 5 [/SUP], Naim Ata[SUP] 6 [/SUP], Ibrahim Sahin[SUP] 7 [/SUP], Rifat Emral[SUP] 8 [/SUP], Erman Cakal[SUP] 9 [/SUP], Aysegul Atmaca[SUP] 10 [/SUP], Mustafa Sahin[SUP] 8 [/SUP], Osman Celik[SUP] 11 [/SUP], Tevfik Demir[SUP] 12 [/SUP], Derun Ertugrul[SUP] 13 [/SUP], Ugur Unluturk[SUP] 4 [/SUP], Murat Caglayan[SUP] 14 [/SUP], Ilhan Satman[SUP] 15 16 [/SUP]



Affiliations

Abstract

Background: Coronavirus disease 2019 (COVID-19) has been reported to be associated with a more severe course in patients with type 2 diabetes (T2DM). However, severe adverse outcomes are not recorded in all patients. In this study, we assessed disease outcomes in patients with and without T2DM hospitalized for COVID-19.
Methods: A nationwide retrospective cohort of patients with T2DM hospitalized with confirmed COVID-19 infection from 11 March to 30 May 2020 in the Turkish Ministry of Health database was investigated. Multivariate modeling was used to assess the independent predictors of demographic and clinical characteristics with mortality, length of hospital stay, and intensive care unit (ICU) admission and/or mechanical ventilation.
Results: A total of 18,426 inpatients [median age (IQR): 61 (17) years, males: 43.3%] were investigated. Patients with T2DM(n=9213) were compared to a group without diabetes (n=9213) that were matched using the propensity scores for age and gender. Compared to the group without diabetes mellitus, 30 days mortality following hospitalization was higher in patients with T2DM (13.6% vs 8.7%; HR: 1.75 95% CI: 1.58-1.93, p<0.001). The independent associates of mortality were older age, male gender, obesity, insulin treatment, low lymphocyte count, and pulmonary involvement on admission. Older age, low lymphocyte values, and pulmonary involvement at baseline were independently associated with longer hospital stay and/or ICU admission.
Conclusions: The current study from the Turkish national healthcare database showed that patients with T2DM hospitalized for COVID-19 are at increased risk of mortality, longer hospital stay, and ICU admission.

Keywords: COVID-19; hospital stay; intensive care unit admission; mortality; type 2 diabetes.
 
Back
Top Bottom